<DOC>
	<DOCNO>NCT00897338</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood pleural peritoneal fluid patient metastatic breast cancer laboratory may help doctor identify biomarkers relate breast cancer learn breast cancer begin spread body . PURPOSE : This research study look new way identify circulate breast cancer cell blood pleural peritoneal fluid woman metastatic breast cancer .</brief_summary>
	<brief_title>Identifying Circulating Breast Cancer Cells Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare identification circulate breast cancer cell ( CBCCs ) blood pleural peritoneal fluid novel technique use stem cell marker retinaldehyde dehydrogenase ( ALDH ) surface antigen expression ( CD44+ , CD24- ) standard technique use CellSearch® system woman metastatic breast cancer . Secondary - To determine whether CBCCs potential grow metastatic lesion . OUTLINE : Patients undergo sample collection help develop new technique use stem cell marker retinaldehyde dehydrogenase ( ALDH ) surface antigen expression ( CD44+ , CD24- ) isolate circulate breast cancer cell ( CBCCs ) blood pleural peritoneal fluid . Blood may also draw measure number circulate tumor cell use standard CellSearch® system . Mononuclear cell isolated density centrifugation . Cells stain surface antigen provide specific expression pattern CBCCs ( CD44 , CD24 ) . Cells analyze fluorescence activate cell sort ( FACS ) Calibur flow cytometer sequentially gate ( ALDHhigh→CD44+ vs CD24-/low CD44+ v CD24-/low→ALDHhigh ) detection CBCCs . For confirmation epithelial origin , ALDHhighCD44+CD24-/low cell isolate use FACSAria flow sorter , cytocentrifuged onto glass slide stain expression epithelial-specific cytokeratins 5 , 8 , 14 , 18 19 standard immunohistochemical technique . Using phenotype find highly enrich epithelial cell , cell isolate FACS assay clonogenic growth .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Metastatic disease ( stage IV ) Hormone receptor status specify PATIENT CHARACTERISTICS : Female Menopausal status specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage IV breast cancer</keyword>
</DOC>